Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

David Wheeler, MD

CARE-ID

Disclosure(s): AstraZeneca: Funding for clinical research; Gilead: Funding for clinical research; Janssen: Funding for clinical research

Poster(s):

(P-1969) Safety, Immunogenicity, and Pharmacokinetics of Repeat Dosing with AZD7442 (Tixagevimab/Cilgavimab): Final Analysis of the ENDURE Phase 2, Dose-Ranging Study in Immunocompromised Participants

Saturday, October 19, 2024
12:15 PM – 1:30 PM US PT